Recent Developments ATP Assay Market:
# In March 2019, Promega launched the Water-Glo reagent, which uses bioluminescent technology to measure ATP and is used for monitoring microbial contamination in freshwater, process water, seawater, or wastewater samples.
# In August 2018, Hygiena acquired Biomedal’s Food Safety division. Under this acquisition, the new division will be named Hygiena Diagnóstica España and will provide allergen tests and assays in the market.
# In February 2018, Merck invested around USD 44 million (~EUR 40 million) for expanding its manufacturing and distribution centers in South Korea, India, and China.
# In August 2017, Hach (a subsidiary of Danaher Corporation) expanded its Loveland, US campus by inaugurating a new facility for R&D.
North America dominates the ATP assays industry:
The global market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America accounted for the largest share of the market. The growth of the market in North America is mainly driven by increasing investments in cancer and stem cell research, increasing demand for technologically advanced instruments in research and diagnostic applications, and the high prevalence of chronic diseases coupled with the increasing demand for early and effective disease diagnosis and treatment. The favorable reimbursement policies, high disposable income, and the presence of superior healthcare and research infrastructure are also supporting market growth.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223438780
End Users:
By end user, pharmaceutical & biotechnology companies accounted for the largest market share in 2018
Based on end user, the ATP assays market is segmented into pharmaceutical & biotechnology companies, the food & beverage industry, hospitals & diagnostic laboratories, and academic & research institutions. In 2018, the pharmaceutical & biotechnology companies segment accounted for the largest share of the market. ATP assays are emerging as preferred tools for screening potential drug compounds; therefore, many pharmaceutical and biotechnology companies are gradually replacing other in vitro and biochemical assays with cell-based assays, such as ATP assays, in drug discovery. Owing to the increasing adoption of cell-based assays, the use of ATP assay kits is also likely to increase in the coming years.
Global Key Players:
The prominent players in the global ATP assays market are Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Lonza Group (Switzerland), Promega Corporation (US), Agilent Technologies, Inc. (US), Abcam plc. (UK), Danaher Corporation (US), Hygiena, LLC. (US), BioThema AB (Sweden), Abnova Corporation (Taiwan), AAT Bioquest (US), PromoCell GmbH (Germany), BioVision, Inc. (US), Geno Technology, Inc. (US), Biotium (US), Canvax Biotech S.L. (Spain), Creative Bioarray (US), Elabscience (US) and MBL International Corporation (US).
Key Questions Addressed in the Report
# Which are the top 10 players operating in the ATP assays market?
# What are the drivers, restraints, opportunities, and challenges of the market?
# What are the prevailing industry trends, and what is the current scenario in the market?
# What are the growth trends in the market at the segmental and overall levels?
# How is the market performing in different regions across the globe?
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=223438780
Data Triangulation:
After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Expected Revenue Growth:
The global ATP assays market size is projected to reach USD 315 million by 2024 from USD 191 million in 2019, at a CAGR of 10.5%. Growth in this market is majorly driven by the increasing demand for ATP assays in pharmaceutical & biotechnology companies, rising investments in pharmaceutical & biotechnology R&D, the increasing prevalence of cancer and other chronic and infectious diseases, and the shift from culture-based tests to rapid tests.
ATP Assay Market - Future Growth Dynamics & Expected Revenue Growth
What This Report Will Provide?Genotyping platforms have several potential application areas such as pharmacogenomics, diagnostic research, personalized medicine, and forensics.
Furthermore, this technology is also apt for a range of veterinary needs, food safety and quality, and environmental testing in remote areas and industrial settings.
At present, human diagnostics and pharmacogenomics offer significant marker potential as these segments require rapid genotyping analysis on a large scale due to the need for better treatment options and high disease prevalence.Expected Revenue Growth:MarketsandMarkets forecasts the Genotyping Assay market to grow from USD 11.8 billion in 2018 to USD 31.9 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 22.0% during the forecast period.Major Growth Boosters:The major factors that are expected to be driving the genotyping assay market are technological advancements and the decreasing prices of DNA sequencing.
The increasing incidence of genetic diseases and rising awareness of personalized medicine, growing importance of genotyping in drug development, and the increasing demand for bioinformatics solutions in data analysis are also expected to promote market growth in the coming years.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595The sequencing segment is expected to witness a faster growth rate in this market due to factors such as, the increasing application areas of DNA sequencing technologies, technological advancements, the availability of high-speed sequencing instruments, and the growing uptake of the hybrid approach of sequencing.Critical questions the report answers:1.
Where will all these developments take the industry in the long term?2.
What are the upcoming trends for the genotyping market?3.
According to the new market research report “Genotyping Assay Market by Technology (PCR, Sequencing, Microarray, Electrophoresis, MALDI-TOF), Application (Pharmacogenomics, Diagnostic Research, Animal Genetics, Agricultural Biotechnology), and Product – Global Forecast to 2023”, , published by MarketsandMarkets™,Genotyping Assay market to grow from USD 11.8 billion in 2018 to USD 31.9 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 22.0% during the forecast periodBrowse in-depth TOC on “Genotyping Assay Market”219 – Tables53 – Figures280 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595The major factors that are expected to be driving the genotyping assay market are technological advancements and the decreasing prices of DNA sequencing.
The increasing incidence of genetic diseases and rising awareness of personalized medicine, growing importance of genotyping in drug development, and the increasing demand for bioinformatics solutions in data analysis are also expected to promote market growth in the coming years.
The objective of the report is to define, describe, and forecast the genotyping assay market size based on product & service, technology, application, end user, and region.Genotyping Assay market is estimated to be the largest segment for the marketBy product & service, the reagents and kits segment is expected to grow at the highest growth rate during the forecast period :Among the product & service, segment, the reagents and kits segment is expected to grow at the highest CAGR during the forecast period.
The factors attributing to the high growth are, the accessibility of a wide range of reagents, the increasing demand for reagents owing to the increasing genotyping test volumes across the globe, and the relatively smaller capital investment required to adopt reagents and kits for genotyping in pharmaceuticals and diagnostic centers.Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595By technology, the sequencing segment to record the highest CAGR during the forecast periodThe sequencing segment is expected to witness a faster growth rate in this market due to factors such as, the increasing application areas of DNA sequencing technologies, technological advancements, the availability of high-speed sequencing instruments, and the growing uptake of the hybrid approach of sequencing.By application, the pharmacogenomics segment is expected to account for the largest share of the genotyping assay marketOn the basis of application, the genotyping market is segmented into pharmacogenomics, diagnostics & personalized medicine, agricultural biotechnology, animal genetics, and other applications.The pharmacogenomics segment is expected to account for the largest share of the genotyping market during the forecast period.
The large share of this segment can be attributed to the increasing use of genotyping to predict the efficiency of drugs during drug development and the growing need to understand the adverse effects of drugs.Prominent players in the Genotyping Assay Market are Thermo Fisher Scientific (US), Illumina (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US)To speak to our analyst for a discussion on the above findings, click Speak to Analyst@ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=249958595
What This Report Will Provide?Genotyping platforms have several potential application areas such as pharmacogenomics, diagnostic research, personalized medicine, and forensics.
Furthermore, this technology is also apt for a range of veterinary needs, food safety and quality, and environmental testing in remote areas and industrial settings.
At present, human diagnostics and pharmacogenomics offer significant marker potential as these segments require rapid genotyping analysis on a large scale due to the need for better treatment options and high disease prevalence.Expected Revenue Growth:MarketsandMarkets forecasts the Genotyping Assay market to grow from USD 11.8 billion in 2018 to USD 31.9 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 22.0% during the forecast period.Major Growth Boosters:The major factors that are expected to be driving the genotyping assay market are technological advancements and the decreasing prices of DNA sequencing.
The increasing incidence of genetic diseases and rising awareness of personalized medicine, growing importance of genotyping in drug development, and the increasing demand for bioinformatics solutions in data analysis are also expected to promote market growth in the coming years.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595The sequencing segment is expected to witness a faster growth rate in this market due to factors such as, the increasing application areas of DNA sequencing technologies, technological advancements, the availability of high-speed sequencing instruments, and the growing uptake of the hybrid approach of sequencing.Critical questions the report answers:1.
Where will all these developments take the industry in the long term?2.
What are the upcoming trends for the genotyping market?3.
According to the new market research report “Genotyping Assay Market by Technology (PCR, Sequencing, Microarray, Electrophoresis, MALDI-TOF), Application (Pharmacogenomics, Diagnostic Research, Animal Genetics, Agricultural Biotechnology), and Product – Global Forecast to 2023”, , published by MarketsandMarkets™,Genotyping Assay market to grow from USD 11.8 billion in 2018 to USD 31.9 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 22.0% during the forecast periodBrowse in-depth TOC on “Genotyping Assay Market”219 – Tables53 – Figures280 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595The major factors that are expected to be driving the genotyping assay market are technological advancements and the decreasing prices of DNA sequencing.
The increasing incidence of genetic diseases and rising awareness of personalized medicine, growing importance of genotyping in drug development, and the increasing demand for bioinformatics solutions in data analysis are also expected to promote market growth in the coming years.
The objective of the report is to define, describe, and forecast the genotyping assay market size based on product & service, technology, application, end user, and region.Genotyping Assay market is estimated to be the largest segment for the marketBy product & service, the reagents and kits segment is expected to grow at the highest growth rate during the forecast period :Among the product & service, segment, the reagents and kits segment is expected to grow at the highest CAGR during the forecast period.
The factors attributing to the high growth are, the accessibility of a wide range of reagents, the increasing demand for reagents owing to the increasing genotyping test volumes across the globe, and the relatively smaller capital investment required to adopt reagents and kits for genotyping in pharmaceuticals and diagnostic centers.Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595By technology, the sequencing segment to record the highest CAGR during the forecast periodThe sequencing segment is expected to witness a faster growth rate in this market due to factors such as, the increasing application areas of DNA sequencing technologies, technological advancements, the availability of high-speed sequencing instruments, and the growing uptake of the hybrid approach of sequencing.By application, the pharmacogenomics segment is expected to account for the largest share of the genotyping assay marketOn the basis of application, the genotyping market is segmented into pharmacogenomics, diagnostics & personalized medicine, agricultural biotechnology, animal genetics, and other applications.The pharmacogenomics segment is expected to account for the largest share of the genotyping market during the forecast period.
The large share of this segment can be attributed to the increasing use of genotyping to predict the efficiency of drugs during drug development and the growing need to understand the adverse effects of drugs.Prominent players in the Genotyping Assay Market are Thermo Fisher Scientific (US), Illumina (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US)To speak to our analyst for a discussion on the above findings, click Speak to Analyst@ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=249958595